[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=17141f78b69e7f4ead5e8b3c965faa1df0789b425cc09cb8716f0a38d7b59df3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759941180,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 137078234,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=17141f78b69e7f4ead5e8b3c965faa1df0789b425cc09cb8716f0a38d7b59df3"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend",
    "summary": "Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. The $10 billion acquisition of Verona Pharma plc (NASDAQ:VRNA) by Merck & Co. (NYSE:MRK), which offered $107 per American Depositary Share, was authorized by the company’s shareholders on October 1. After a planned […]",
    "url": "https://finnhub.io/api/news?id=ac53efcb30d766b6ad21b4c534c2823f26fe8b992df073103f84532a55daaebc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759932308,
      "headline": "Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend",
      "id": 137010954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. The $10 billion acquisition of Verona Pharma plc (NASDAQ:VRNA) by Merck & Co. (NYSE:MRK), which offered $107 per American Depositary Share, was authorized by the company’s shareholders on October 1. After a planned […]",
      "url": "https://finnhub.io/api/news?id=ac53efcb30d766b6ad21b4c534c2823f26fe8b992df073103f84532a55daaebc"
    }
  },
  {
    "ts": null,
    "headline": "Chart Expert Says Merck (MRK) Has More Upside – Here’s Why",
    "summary": "We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks. Carter Worth from Worth Charting said in a latest program on CNBC that Merck & Co Inc (NYSE:MRK) is one of the stocks that has more […]",
    "url": "https://finnhub.io/api/news?id=1bdc9e35ee801f8876500e3fc7a62970f2acbf3804582a975320531593f8682e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759930107,
      "headline": "Chart Expert Says Merck (MRK) Has More Upside – Here’s Why",
      "id": 137010955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks. Carter Worth from Worth Charting said in a latest program on CNBC that Merck & Co Inc (NYSE:MRK) is one of the stocks that has more […]",
      "url": "https://finnhub.io/api/news?id=1bdc9e35ee801f8876500e3fc7a62970f2acbf3804582a975320531593f8682e"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
    "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
    "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927800,
      "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
      "id": 137010956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
      "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8"
    }
  },
  {
    "ts": null,
    "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
    "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
    "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927320,
      "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
      "id": 137010911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25"
    }
  },
  {
    "ts": null,
    "headline": "Transjovan Capital participates at the 69th Annual General Meeting of the Indo-German Chamber of Commerce",
    "summary": "The Indo-German Chamber of Commerce hosted its 69th Annual General Meeting on 24th September 2025 in Mumbai. As a member firm, Transjovan Capital's Managing Partner, Gaurav Asthana attended the annual event.",
    "url": "https://finnhub.io/api/news?id=2db2d7207d3f7a3428e8f5eafc01d677cca5639e82c3f41768868db198462e95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759922880,
      "headline": "Transjovan Capital participates at the 69th Annual General Meeting of the Indo-German Chamber of Commerce",
      "id": 137010076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Indo-German Chamber of Commerce hosted its 69th Annual General Meeting on 24th September 2025 in Mumbai. As a member firm, Transjovan Capital's Managing Partner, Gaurav Asthana attended the annual event.",
      "url": "https://finnhub.io/api/news?id=2db2d7207d3f7a3428e8f5eafc01d677cca5639e82c3f41768868db198462e95"
    }
  },
  {
    "ts": null,
    "headline": "Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics",
    "summary": "The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors, and an aging population, underscoring the urgent need for early detection and innovative treatments. Breakthroughs in immunotherapy and targeted treatments, such as immune checkpoint inhibitors, are transforming care strategies. Public awareness initiatives enhance early d",
    "url": "https://finnhub.io/api/news?id=c32ba4d6b06080971780201d1de62e3d9cbddbb82a9ae9b1522c6f90d923c920",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759914720,
      "headline": "Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics",
      "id": 137010077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors, and an aging population, underscoring the urgent need for early detection and innovative treatments. Breakthroughs in immunotherapy and targeted treatments, such as immune checkpoint inhibitors, are transforming care strategies. Public awareness initiatives enhance early d",
      "url": "https://finnhub.io/api/news?id=c32ba4d6b06080971780201d1de62e3d9cbddbb82a9ae9b1522c6f90d923c920"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK): Assessing Valuation Following Recent Month’s Modest Share Price Increase",
    "summary": "Merck (MRK) has recently wrapped up another month of trading, sparking renewed discussion about its longer-term performance. Investors are evaluating the stock’s modest month climb and considering how it compares to the company’s broader track record. See our latest analysis for Merck. After a solid start to the year, Merck’s share price has slipped by 11.66% year-to-date, despite a few short bursts of momentum in recent weeks. Over the last twelve months, total shareholder return of -16.28%...",
    "url": "https://finnhub.io/api/news?id=401541d5d875f26c5cda5740bd2b5baa7c1e0680290a90c7804f3f4a3421e479",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759911577,
      "headline": "Merck (MRK): Assessing Valuation Following Recent Month’s Modest Share Price Increase",
      "id": 137010078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has recently wrapped up another month of trading, sparking renewed discussion about its longer-term performance. Investors are evaluating the stock’s modest month climb and considering how it compares to the company’s broader track record. See our latest analysis for Merck. After a solid start to the year, Merck’s share price has slipped by 11.66% year-to-date, despite a few short bursts of momentum in recent weeks. Over the last twelve months, total shareholder return of -16.28%...",
      "url": "https://finnhub.io/api/news?id=401541d5d875f26c5cda5740bd2b5baa7c1e0680290a90c7804f3f4a3421e479"
    }
  },
  {
    "ts": null,
    "headline": "Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations",
    "summary": "LONDON, October 08, 2025--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.",
    "url": "https://finnhub.io/api/news?id=29788823be757dd4838d896daad59de0b854847de1b905b10d9e03647d780af5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759906800,
      "headline": "Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations",
      "id": 137009136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON, October 08, 2025--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.",
      "url": "https://finnhub.io/api/news?id=29788823be757dd4838d896daad59de0b854847de1b905b10d9e03647d780af5"
    }
  },
  {
    "ts": null,
    "headline": "BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma",
    "summary": "LUND, SE / ACCESS Newswire / October 8, 2025 /BioInvent International AB (\"BioInvent\") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...",
    "url": "https://finnhub.io/api/news?id=9cd8be60038dcf78df544954e9505309b9fc4d0c2165e4ec409d5846e1fa8f9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759904100,
      "headline": "BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma",
      "id": 137010080,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LUND, SE / ACCESS Newswire / October 8, 2025 /BioInvent International AB (\"BioInvent\") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...",
      "url": "https://finnhub.io/api/news?id=9cd8be60038dcf78df544954e9505309b9fc4d0c2165e4ec409d5846e1fa8f9b"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. An American multinational pharmaceutical company, Merck & Co., Inc. (NYSE:MRK) is one of the most profitable stocks that pay dividends, with a trailing twelve-month net profit margin of 25.8%. Finding new medicines is a complex process, and […]",
    "url": "https://finnhub.io/api/news?id=59486734bd2e8e988bdfd2066383e05924867da66e013bca8000fa0cc4845c4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759902550,
      "headline": "Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks",
      "id": 137008021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. An American multinational pharmaceutical company, Merck & Co., Inc. (NYSE:MRK) is one of the most profitable stocks that pay dividends, with a trailing twelve-month net profit margin of 25.8%. Finding new medicines is a complex process, and […]",
      "url": "https://finnhub.io/api/news?id=59486734bd2e8e988bdfd2066383e05924867da66e013bca8000fa0cc4845c4f"
    }
  }
]